In 2028, around 15.3 billion U.S. dollars of Keytruda sales are expected to be at risk due to the drug patent expiring. This statistic illustrates the sales at risk of pharmaceutical products in the U.S. due to approaching drug patent expiries, as of 2022.
Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022
(in billion U.S. dollars)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Evaluate Vantage. (May 25, 2022). Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022 (in billion U.S. dollars) [Graph]. In Statista. Retrieved November 10, 2024, from https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/
Evaluate Vantage. "Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022 (in billion U.S. dollars)." Chart. May 25, 2022. Statista. Accessed November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/
Evaluate Vantage. (2022). Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022 (in billion U.S. dollars). Statista. Statista Inc.. Accessed: November 10, 2024. https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/
Evaluate Vantage. "Sales at Risk of Leading Pharmaceutical Products in The U.S. Due to Approaching Drug Patent Expiries as of 2022 (in Billion U.S. Dollars)." Statista, Statista Inc., 25 May 2022, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/
Evaluate Vantage, Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022 (in billion U.S. dollars) Statista, https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/ (last visited November 10, 2024)
Sales at risk of leading pharmaceutical products in the U.S. due to approaching drug patent expiries as of 2022 (in billion U.S. dollars) [Graph], Evaluate Vantage, May 25, 2022. [Online]. Available: https://www-statista-com.ezproxy.canberra.edu.au/statistics/1315574/top-drugs-sales-at-risk-due-to-patent-expiries/
